Literature DB >> 19760066

Targeting of BAFF and APRIL for autoimmunity and oncology.

Maureen C Ryan1, Iqbal S Grewal.   

Abstract

BLyS and APRIL are tumor necrosis factor superfamily members shown to be important for B-cell development, maturation and survival. Recent data also indicate that these cytokines regulate the survival and maintenance of malignant B-cells in cancer patients. The key role of BlyS/APRIL in the immune system and their potential role in cancers have attracted the attention of basic scientistis and biotechnology companies alike. As a result, the pathways regulated by BLYS and APRIL have been quickly elevated as attractive targets for antibody-based and non-antibody based therapeutics. Exploitation of these pathways has not only given us enormous insights into the basic biology of the APRIL/BLyS system but it has also identified potential clinical candidates for cancer and autoimmunity. As such, multiple biotechnology companies are currently testing various therapeutic candidates in the clinic. This chapter will review BLyS and APRIL functions and discuss alternative therapeutic approaches to target BLyS and APRIL pathways for human malignancies and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760066     DOI: 10.1007/978-0-387-89520-8_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

Review 1.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

2.  Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.

Authors:  Debra D Bloom; Sofiya Reshetylo; Cassandra Nytes; Claudia T Goodsett; Peiman Hematti
Journal:  J Immunother       Date:  2018-06       Impact factor: 4.456

Review 3.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 4.  B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.

Authors:  Ronald F Parsons; Kumar Vivek; Robert R Redfield; Thi-Sau Migone; Michael P Cancro; Ali Naji; Hooman Noorchashm
Journal:  Transplant Rev (Orlando)       Date:  2010-07-23       Impact factor: 3.943

Review 5.  TNF superfamily protein-protein interactions: feasibility of small- molecule modulation.

Authors:  Yun Song; Peter Buchwald
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

6.  Lupus nephritis: an overview of recent findings.

Authors:  Alberto de Zubiria Salgado; Catalina Herrera-Diaz
Journal:  Autoimmune Dis       Date:  2012-03-22

7.  The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer.

Authors:  Marilena Kampa; George Notas; Efstathios N Stathopoulos; Andreas Tsapis; Elias Castanas
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

8.  BAFF receptor antibody for mantle cell lymphoma therapy.

Authors:  Keman Zhang; Nand K Roy; Yorleny Vicioso; Janghee Woo; Rose Beck; Marcos de Lima; Paolo Caimi; Daniel Feinberg; Reshmi Parameswaran
Journal:  Oncoimmunology       Date:  2021-03-05       Impact factor: 8.110

9.  TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss.

Authors:  Guangchao Li; Qing Zhang; Zhi Liu; Huijuan Shen; Yangmin Zhu; Zhao Zhou; Wen Ding; Siqi Han; Jie Zhou; Ruiming Ou; Min Luo; Shuang Liu
Journal:  Cancer Cell Int       Date:  2021-04-17       Impact factor: 5.722

10.  Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Michael Schiff; Bernard Combe; Thomas Dörner; Joel M Kremer; Thomas W Huizinga; Melissa Veenhuizen; Anne Gill; Wendy Komocsar; Pierre-Yves Berclaz; Robert Ortmann; Chin Lee
Journal:  RMD Open       Date:  2015-08-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.